Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lenses may reveal how to slow nearsightedness in kids

NCT ID NCT05617794

Knowledge-focused Sponsor: SightGlass Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether special spectacle lenses called Diffusion Optics Technology (DOT) lenses can change the thickness of the choroid, a layer of blood vessels in the eye. Researchers will measure these changes in 30 children aged 8-14 with normal vision after wearing the lenses for 30 and 60 minutes. The goal is to understand how these lenses might help control myopia (nearsightedness) progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diffusion Optics Technology (DOT) spectacle lenses
What this could lead to
If successful, this could help explain how DOT lenses might slow myopia progression in children.
What could go wrong
This is a small, early-stage study measuring short-term eye changes, not long-term vision outcomes. Results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 14 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are 8-14 years of age; * Are able to read (or be read to), understand and sign the assent document; * Are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document; * Are emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D inclusively; * Are willing and able to follow instructions. Exclusion Criteria: * Are participating in any concurrent interventional clinical or research study; * Have a history of myopia control treatment in the past year; * Have amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency; * Have any known active ocular disease and/or infection; * Have a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism; * Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops; * Have undergone strabismus surgery, refractive error surgery or intraocular surgery; * Are a child of a member of the study team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myopia Myopia Myopia progression

Contacts and locations

Locations

  • Centre for Ocular Research and Education

    Waterloo, Ontario, N2L 3G1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.